DCM
DMAC icon

DAFNA Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

DAFNA Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-156,529
Closed -$664K – 81
2020
Q3 		$664K Buy
+156,529
New +$828K 0.22% 69

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAFNA Capital Management's DMAC Position: Q4 2020 in Review

DAFNA Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q4 2020, closing a stake of 156,529 shares — an estimated $664K sold.

DAFNA Capital Management first reported a position in DMAC in Q3 2020 and held it in 1 quarter. The position peaked at $664K in Q3 2020. 36 funds tracked by Wall St. Rank hold DMAC as of Q4 2020.

  • DAFNA Capital Management reported no remaining DiaMedica Therapeutics position as of Q4 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 156,529 DiaMedica Therapeutics shares in Q4 2020, an estimated $664K.
  • DAFNA Capital Management first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 1 quarter.
  • DAFNA Capital Management's DiaMedica Therapeutics position peaked at $664K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2020.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.